Date: 2016-09-01
Type of information: Nomination
Compound:
Company: Halozyme Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 1, 2016, Halozyme Therapeutics named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer. Mark J. Gergen will be responsible for corporate development, including the management of Halozyme's proprietary Enhanze™ platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme's oncology pipeline, including clinical operations and clinical collaborations. Gergen joins Halozyme most recently from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer reporting to the CEO and responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions. He executed multiple successful partnerships, collaborations and licensing agreements. Before Mirati, he spent 7 years at Amylin Pharmaceuticals as a member of the executive committee reporting to the CEO, where he led corporate development and alliances.
Financial terms:
Latest news:
